Cell Technology Inc., a biotechnology firm, based in Boulder, Colo., that specializes in biological response modification, has entered into an agreement with Utah State University to evaluate promising treatments for patients diagnosed with AIDS.

The research agreement is with Dr. Robert Sidwell, professor of immunology and virology and director of the Anti-Viral Program at USU. He directs one of two major contract laboratories in the United States funded by National Institutes of Health, which performs screening for potential AIDS patients.The studies to be undertaken in connection with that research agreement are designed to evaluate the effectiveness of Cell Technology's anti-viral BRM, Aviron, utilizing the Friend leukemia virus model. This model, one of the two major screening models employed by the National Institutes of Health's AIDS screening program, will parallel work under way at the National Cancer Institute, Bethesda, Md.

Testing of Aviron with Sidwell and at the National Cancer Institute continues the work undertaken by Cell Technology in connection with developing this BRM product for the treatment of patients with AIDS and Aids Related Complex.

Through these studies, Cell Technology intends to apply for inclusion of Aviron in a national study potentially involving clinical trials to be supported by federal funding of a multicenter AIDS trial at sites throughout America.

"These studies are critical to our understanding of Aviron's mechanism as well as establishing the potential clinical utility of Aviron in the treatment of AIDS patients," said Dr. Frederick C. Pearson, the company's vice president of scientific operations. "This research program will propel the company's efforts significantly as it moves toward the utilization of human clinical testing of Aviron in AIDS/ARC patients."

Cell Technology Inc. is a biotechnology company specializing in immunotherapy. The company's innovative biologic response modifier products are being developed to activate the body's immune response to fight cancer, vascular disease, viral infections and to act as a general immunomodulating agent.